This inventor holds 1 USPTO granted patent. Top assignee: Xencor, Inc.. Active years: 2009.
Company Filing History:
Years Active: 2009
Title: The Innovations of Adam Read Thomason
Introduction
Adam Read Thomason is an accomplished inventor based in San Francisco, CA. He has made significant contributions to the field of biotechnology, particularly in the development of novel proteins that have therapeutic potential. His work focuses on addressing disorders related to BAFF and APRIL, which are crucial in various immune responses.
Latest Patents
Thomason holds a patent for "BAFF variants and methods thereof." This invention relates to novel proteins that exhibit BAFF dominant negative antagonist, receptor antagonist activity, and agonist activity. Additionally, it includes nucleic acids encoding these proteins. The invention is particularly relevant for the treatment of BAFF or APRIL-related disorders, showcasing Thomason's innovative approach to addressing complex medical challenges.
Career Highlights
Thomason is currently employed at Xencor, Inc., a company known for its advancements in biopharmaceuticals. His role at Xencor allows him to leverage his expertise in protein engineering and therapeutic development. With a patent portfolio that includes 1 patent, he continues to push the boundaries of scientific research and innovation.
Collaborations
Thomason has collaborated with notable colleagues, including John R Desjarlais and Eugene Alexander Zhukovsky. These partnerships enhance the research environment and foster the exchange of ideas, contributing to the advancement of their collective work in biotechnology.
Conclusion
Adam Read Thomason exemplifies the spirit of innovation in the field of biotechnology. His contributions, particularly in the development of BAFF variants, highlight the potential for new treatments for immune-related disorders. Through his work at Xencor, he continues to make strides in improving healthcare outcomes.